2
consistently elevated across a range of chronic inflammatory diseases affecting either single systems or multi-system inflammatory disorders. C-reactive protein (CRP) was analysed as an index of inflammation severity.
Methods

Data
A matched cohort study was implemented using data from the Clinical Practice Research Datalink (CPRD). The CPRD is the world's largest primary care database comprising anonymised longitudinal electronic patient records from primary care. The CPRD includes extensive clinical, diagnostic, pharmacological, demographic, and hospital information on over 12 million UK primary care patients from over 650 family practices. Data reaching predefined quality standards are referred to as 'up-to-standard'. 8 The size and geographical distribution of general practices, as well as the age and sex of individuals included in the database are broadly representative of the UK population. The high quality of CPRD diagnostic and prescription information has been documented in several studies. sampled from the CPRD. In order to adopt an inclusive approach, and avoid bias in the selection of specific diagnostic categories, the study protocol specified the selection of broad categories from the Read code hierarchy (Supplemental Table) . These included organ-specific chronic inflammatory disorders including: psoriasis and similar disorders (M16, subsequently excluding extensive clinical, diagnostic, pharmacological, demographic, and hospital inform rm mat at tio ion n n on on on o o ove ve v r 12 million UK primary care patients from over 650 family practices. Data reaching predefined qu qual al alit it ity y y t st stan an anda da dard ds s s a ar are e referred to as 'up-to-standar ar ard' d'. 8 The size an nd d d geog og gr ra raphical distribution of g gen ne neral practice ces s s, a as s w w well ll ll a a as s th th the e ag ag ge e e an an nd d sex x o of f ind d di iv vid dua ua uals ls i in nc cl lu ud de ed d i in n th he da da dat ta taba bas s se a a are re e b b br ro road ad a l ly y e epr pr pres es sen en e ta tati ti tive v ve o of f f th h he e UK UK UK p pop p pul ul ula a ati ti tion on on. or 'severe' psoriasis as reported previously. 3 Psoriasis was broken down into severe and mild because previous research suggested that the burden of comorbidity increases with disease severity, inclusion of mild cases, as well as severe, allowed evaluation of this possibility. 3, 11, 12 Participants with a diagnosis of chronic inflammatory disease were matched on age, gender, and family practice with up to two controls randomly sampled from all patients in the CPRD never diagnosed with a chronic inflammatory disorder. Data were extracted from the CPRD in February 2013.
Outcomes
The study outcomes included new diagnoses of CHD (including myocardial infarction, angina, coronary artery bypass graft, percutaneous coronary transluminal angioplasty), stroke, and T2DM. This cluster of outcomes was selected because chronic inflammation may be associated herapy (including methotrexate, azathioprine, cyclosporine, hydroxyurea) and phototherapy P PUV UV UVA) A) A) t t tre re reat at atme ent nt nt w were used to further differen nti ti tiat ate e psoriasis par rti ti t cipa pa ant nt nts s into those with 'mild' or 'se severe' psor oria ia i s sis a as s r r rep ep por or orte te ted d pr pr rev ev evio o ou us sly. 3 3 3 P P Psor ri ia asis w w was as b br ro roke ke en n do dow wn wn int nt to o se seve ve ere re e a and nd n m m mil l ild d
be eca ca caus us use e pr pr prev ev evi io ious us s r r res esea earc rc ch h su u ugg gg g es es este te ted d d t t tha ha at t t th th the bu bu bur rd de en en o o of f co co como mo morb rb r i id idit it ity y y in in ncr r rea eas se ses s s wi wi ith th th dis is sea a ase se everity, incl lus us usio io i n n n of of o m m mil i i d d ca ca case se s s, s, s, a a as s we we well ll l a a as s se se seve ve v re re r , , al al a lo lowe we wed d d ev ev eval al alua u u ti ti tion on on o o of f f th th this is p p pos os ossi si ibi bi bili l ty.
with vascular and metabolic changes including endothelial dysfunction and insulin resistance which may precede both CVD and T2DM. 13 Read medical codes 10, 14 were used to identify incident stroke and CHD events during the study period. T2DM was diagnosed using definitions reported previously with the diagnosis date being the earlier of the first medical code and the first diabetes prescription. 15 Participants diagnosed with type I diabetes were excluded from the study.
The date of the first outcome code is referred to as the respective outcome index date. Multiple morbidity was defined as the occurrence of two or more outcomes in a participant.
Biomarker
Recorded CRP values were analysed as biomarker for inflammation severity. The mean of CRP values recorded from 3 months prior to study start date to the study end date was included grouping patients into tertiles of CRP values, in line with previous studies. 16 Tertiles were defined separately for CI patients and controls owing to the differing distributions.
Confounders
Several variables known to be associated with CVD and T2DM risk were included as covariates. 17 These included body mass index (BMI; <18.5, 18.5 to 25, >25 to < 30, 30 to <35, and 35
Kg/m 2 ), smoking (never, ex-smoker, current smoker), drinking (never, ex-drinker, current drinker), systolic and diastolic blood pressure (BP) (<120/80 mmHg normal, 120-139/80-89 mmHg prehypertension, 140/90 mmHg hypertension), total cholesterol (<5.2 mmol/L (desirable), 5.2 to 6.2 mmol/L (elevated), and >6.29 mmol/L (high)) , quartiles of creatinine levels ( mol/L), and whether glucocorticoids, statins, and antihypertensive drugs were prescribed. The categories for blood pressure and cholesterol derive from American Heart Association guidelines. 18, 19 For each confounder, the value closest to the study baseline and before chronic inflammation diagnosis was included. The models also included age, age squared values recorded from 3 months prior to study start date to the study end date was s i inc nc nclu u ude de ded d d grouping patients into tertiles of CRP values, in line with previous studies. 16 Tertiles were de efi fi fine ne ned d d se se epa pa par r rate ely ly ly f for CI patients and controls o o ow w win n ng to the differ r rin i i g di di dist st stri r butions.
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(to test for possible non-linearity association), and gender as confounders.
Statistical analysis
The analyses were conducted in a time-to-event framework. Participants contributed person-time to the analysis from the study start date (the later of the start of the participant's record in CPRD, or the diagnosis date for chronic inflammatory condition). Follow-up ended at the earliest of the study outcome index date, date of death, or the end of the CPRD record. All participants had at least 12 months of follow-up record and outcomes of interest were only considered after the first 12 months of the follow-up. Cox proportional hazards model was implemented using a multiple-failure framework for unordered events of different types. 20 The pa ati ti ien en ent t t ca can n n ex ex xpe eri ri rie en ence one or more of the differe e en nt n o outcomes of i int nt n eres es st t t i in in an unordered fashion.
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http://circ.ahajournals.org/ Downloaded from analyses estimated the specific associations between each inflammatory condition and CHD, stroke, T2DM, and multi-morbidity in separate Cox regression models. The same estimation models were used for CRP analyses. Sensitivity analyses were also conducted using competing risk analysis 25 to explore the rate of CHD, stroke, and T2DM when death was considered a competing event. Analyses were adjusted for study covariates, including matched variables and age squared (to test for possible non-linearity association). Matching variable were adjusted in the estimation models because in the presence of censoring (e.g. loss to follow-up, competing risks), the balance produced by matching may be lost during follow-up, making it necessary to adjust for matching variables in the analysis. 26 Where data for categorical confounders was not available missing indicator variables were used. No adjustment for multiple comparisons was made so that marginally significant results may be type I errors. However, as the meta-analysis intends a general conclusion as opposed to a specific treatment recommendation, the unadjusted p-values seem better suited to an exploratory analysis. The proportionality hazard assumptions were assessed using Schoenfeld residuals and found not to be violated in most models. In models where covariates, including age, failed the proportionality assumption, these were modelled as time-varying covariates in sensitivity analyses. A random effects meta-analysis 27 was
implemented to obtain a pooled estimate of the risk of CVD and T2DM events across all eight inflammatory conditions. Data were analysed using STATA version 12.
Human studies
The study was approved by the Independent Scientific Advisory Committee (ISAC; Ref: . No patient consent required.
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Results
The study cohorts included 5,648 participants with severe psoriasis, 85,232 with mild psoriasis and related disorders, and 4,284 with bullous skin disorders, 12,203 with ulcerative colitis, 7,628 with Crohn's disease, 27,358 with inflammatory arthritis, 7,472 with systemic autoimmune diseases, and 6,283 with systemic vasculitis ( Table 1) . Diagnosis of multiple inflammatory disorders was observed in fewer than three percent of patients. There were 373,851 matched controls without chronic inflammatory conditions matched for age, gender and family practice.
The extent of missing data among cohort patients ranged from 11% (smoking) to 46% (cholesterol) and from 17% (alcohol) to 56% (cholesterol) among controls.
The characteristics of participants at the start of the study are described in Table 1 . The mean age at study entry was greater for participants diagnosed with bullous skin diseases or systemic vasculitis (69 years) compared to those diagnosed with Crohn's disease (42 years). A higher proportion of women than men were diagnosed with systemic autoimmune diseases including SLE and other connective tissue disorders (83%), as well as inflammatory arthritis (69%), and systemic vasculitis (68%). The crude prevalence of hypertension tended to be greater in systemic vasculitis (50%), while obesity was more frequent in severe psoriasis (23%).
Glucocorticoid prescribing ranged from 13% (Crohn's disease) to 70% (systemic vasculitis). Table 2 shows the frequency of outcome events by condition for participants with chronic inflammatory disorders and their matched controls. The highest numbers of outcome events were observed in systemic vasculitis (13%), bullous skin disorders (9%), and inflammatory arthritis (9%), while the fewest outcomes were observed for Crohn's disease (4%).
In general, a higher proportion of participants with chronic inflammatory disorders experienced outcome events than the control cohort. The absolute risk of outcome events per 1,000 patients in The characteristics of participants at the start of the study are described in in n Ta Ta T bl bl ble e 1 1 1. . Th T The e mean age at study entry was greater for participants diagnosed w r ith bullous skin diseases or y yst st tem em emic ic ic v v vas as a c c culi iti ti tis s s (6 ( 9 years) compared to those e e di dia agnosed with Cr C C oh hn' n' n's s s disease (42 years). A h hi high h her e proport rtio ion n n of of w w wom om men e en t tha h han n m me men n w w were di iagn no nos sed d d w wi with th h s sys yst te em mi mic c a a aut to oim im mm mu mune ne e d d dis is ise e ease se ses s n ncl cl clud ud udin in i g g g SL SL SLE E E an an nd d d ot oth he her r r co conn nn nec ec cti ti tive ve ve t tis is ssu u ue e e d d diso so ord rd rde er ers s (8 (8 83% 3% %), ), ), a a as s s w we well ll ll a a as s in infl flam am mm ma mato to ory ry ry a ar r rth hr hrit itis is s 69%), and s sys ys yste te temi mi m c c c va va v sc s s ul ul ulit it tis i i ( ( (68 68 68%) %) % . Th Th The e e cr cr crud ud ude e p p pre re eva vale le lenc nc nce e e of of of h h hyp yp per er erte te tens ns nsi i ion on on t t ten en Sensitivity analyses using competing risks analyses showed similar patterns wit th h on n ne ex ex e ce ce cept pt ptio i ion: ). An An An es s stim im mat at ate of of o t t the he e e e ext xt ten n nt t to to o w w whi hich ch ch t the e e e e est stim im mat at tes e vary between n d d dif if i fe fe fere re rent nt t c c con n ndi di diti ti t on on ns s s ( (I I I ( No substantive variation in time to event between different inflammatory conditions was observed (median time to event was 4 years for most conditions).
Discussion
This study provides population-level estimates concerning the risk of CVD and T2DM across a wide range of chronic inflammatory disorders. Considering each outcomes separately, an increased risk T2DM events was observed among five of the eight inflammatory conditions; three conditions, including bullous skin diseases, systemic autoimmune diseases, and systemic vasculitis, were associated with increased risk of an incident stroke event; four conditions including severe psoriasis, inflammatory arthritis, ulcerative colitis, and systemic vasculitis, were ndicator variable, and the use of time-varying covariates to validate the potential al l i inf nf n lu u uen en ence ce ce o o of f f non-proportionality assumption. The results of these analyses validated the findings from an nal al alys ys yse es es p p pre re res se ent ted ed ed. Complete case analysis reve e ea al ale ed d marginally hi hi h gher er r e e es stimates than missing n ndi i ica c tor variab ab ble le l a ana naly lysi si sis, s, s b b but ut ut th the e e s si sig gn ni if fican n nc c ce le ev ve e el a and nd nd d di ir i e ec ecti ti n on on o of f f a a ass so oci ci iat at tio ion n we we were re sim im imil l ilar ar r.
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http://circ.ahajournals.org/ Downloaded from associated with elevated CHD risk. An increased risk of two or more of the outcomes was generally observed except in Crohn's disease and systemic autoimmune disorders. There was also evidence for a dose-response association since severe psoriasis was associated with higher rates of T2DM and CHD events relative to mild psoriasis. Sensitivity analysis performed in a competing risk framework, with death as a competing risk, confirmed the individual association findings. Notably, a positive dose-response relationship was apparent between CRP and study outcomes. The relationship tended to be steeper in chronic inflammation patients possibly suggesting a greater risk of both single and multiple CVD outcomes at higher CRP concentrations in chronic inflammation. This association was consistent across inflammation patients and controls supporting the robustness of the relationship. This finding provides some evidence to support the use of CRP to stratify participants according to their risk of CVD as the association was apparent in controls as well as in patients with inflammatory disorders.
The present study presents a novel application of the multiple outcomes model to estimate the risk that participants diagnosed with diverse inflammatory diseases may experience multiple vascular events in an unordered fashion. For example, in one participant T2DM may be followed by stroke, or CHD followed by stroke. This analytical framework indicated an increased risk of CVD and T2DM events across most inflammatory conditions. This suggestion received support from the meta-analysis, which pooled findings across diagnostic cohorts,
leading to a precise estimate of elevated CVD and T2DM risk across diagnostic categories. The largest effect size was observed among systemic diseases including systemic vasculitis and systemic autoimmune disorders. The risk of multiple CVD and T2DM outcomes also appeared to increase with disease severity in Psoriasis. The lack of a dose-relationship between mean CRP tertiles and stroke risk may be due to several factors, including study lower power to detect this patients and controls supporting the robustness of the relationship. This finding p p pro rov vi v de de des s s so so some me m evidence to support the use of CRP to stratify participants according to their risk of CVD as the as sso so oci ci ciat at atio io ion n n w w was ap ap app parent in controls as well as in in n pa atients with inf nf fla l mm mm ma at atory disorders.
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http://circ.ahajournals.org/ Downloaded from association or possibly that this study CRP measure was below a threshold level of exposure beyond which the risk of stroke increases steeply. Also, stroke is often preceded by other CVDs and T2DM, and aggressive treatment of these conditions may confound this association.
The overall incidence of CVD events was consistent with previous studies. 3, 28 The present findings present a more complex picture than previous studies that considered a single outcome measure and a single inflammatory condition. Several studies suggested an increased risk of CHD, stroke, or T2DM events associated with SLE, 7 inflammatory arthritis, 28, 29 and psoriasis. 3, 30, 31 The current findings conducted in a single outcome-single inflammatory condition framework indicated, however, that none of the inflammatory conditions (with the exception of systemic vasculitis) considered here were associated with increased risk across all conditions. In a recent meta-analysis, Samarasekera et al. 32 noted no association between stroke and severe psoriasis. Our analyses which included assessment of multi-morbidity, multiple failure analysis, and meta-analysis suggest that if participants are considered to be at risk of multiple outcomes, psoriasis emerges as being strongly associated with CVD and T2DM events.
Fewer data are available for ulcerative colitis and Crohn's diseases. Yarur et al. 33 found higher rates of vascular events in combined ulcerative colitis and Crohn's disease diagnosed patients.
Present study results imply that ulcerative colitis may be responsible for the observed association. The findings for CRP are in line with previous evidence 16, [34] [35] [36] [37] [38] [39] [40] [41] and extend this evidence to mean CRP values and chronic inflammation patients.
Many experimental models support an association between chronic inflammation with CVD and T2DM. Most attention has focusing on the role of inflammatory cytokines such as interleukins and tumour necrosis factor-alpha to increase oxidative stress, increase insulin resistance and oxidise low-density lipoproteins. 42, 43 These actions which lead to endothelial exception of systemic vasculitis) considered here were associated with increased d ris is sk k ac ac a ro ro ross ss ss a al ll conditions. In a recent meta-analysis, Samarasekera et al. 32 dysfunction are all pro-atherogenic and may contribute to atherosclerotic plaque vulnerable to rupture and initiate a clinical CVD event. 44 The finding that CVD and T2DM events were associated with a wide range of inflammatory conditions strongly supports the hypothesis that any source of chronic inflammation is associated with CVD and T2DM. However, the observational nature of the present study precludes any definitive conclusion regarding causality or mechanism , because increased risk does not imply cause and effect. Indeed a number of alternative mechanisms are possible including increased psychosocial stress, reduced physical activity associated with chronic inflammatory disease, and the possible effects of prescribed therapies including anti-inflammatory drugs. It is also important to note that we cannot distinguish between localised vascular inflammation and systemic inflammation as the potential cause of increased risk. However, it is notable that values of CRP in patients with chronic inflammatory disease were higher than those in cohorts of patients with extensive vascular disease (without other chronic inflammatory disease) and this points to a potential role of systemic inflammation in CVD.
45
Strengths and limitations
The present data derive from a primary care database with documented validity of diagnoses for chronic inflammatory conditions, CHD, stroke and T2DM. The representativeness of the data is well documented ensuring the generalizability of the findings. Several limitations are worth mentioning. We drew on the Read code classification used in UK primary care to provide broad categories of chronic inflammatory disorders for the present analyses. We acknowledge that alternative groupings of conditions might be proposed. However, the aetiology of many of these conditions is poorly understood and classifications based on phenotypic characteristics may sometimes have limited validity. Some diseases (e.g. systemic autoimmune disorders and distinguish between localised vascular inflammation and systemic inflammation n a as th the e e po po pote te tent nt n i ial cause of increased risk. However, it is notable that values of CRP in patients with chronic n nfl fl lam am amm ma mato to tory ry ry dis is sea ea eas se were higher than those in c c coh oh horts of patien nts ts s w n it it th h h e e extensive vascular d di dise e eas a e (witho out ut oth ther er r chr hr hron on onic ic ic i in nfl fl flam am mma ma matory y y d d disea a as se e) an an and d th th hi is s po po oin n nts ts t to o o a a po po ote te tent ntia ia al l l ro ro ole l le o of f f y yst st stem em mic ic i inf nf nfla la lamm mm ma at atio ion n n i in in C CVD VD VD. 45 45
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http://circ.ahajournals.org/ Downloaded from vasculitis) may be located on a spectrum of phenotypic disorders, with disease manifestations varying over time within individuals and varying between different individuals. The present analysis did not take into account disease severity across all inflammatory conditions as there is no agreed definition of severity across different inflammatory conditions. Our findings for increased risk of CHD among severe psoriasis relative to mild psoriasis support similar investigations into other inflammatory conditions. Inflammatory disorder patients may experience more thorough examination from physicians, leading to increased opportunity to identify T2DM, a silent disease. However, inflammation was associated with increased risk of CHD and stroke suggesting that surveillance bias is likely to be minimal here. The study did not explore the impact of over the counter therapy and non-steroidal anti-inflammatory drugs (NSAIDs) on study outcomes, and these could be explored as a potential mechanism in purposefully designed studies. This is an important issue that deserved more explicit attention than possible within the narrow scope of the present study. However, analyses adjusted for glucocorticoid 46 and statins use. Because fewer than 1% of matched controls and only a very small % (<4%) of inflammation patients were on other immunosuppressive therapies (e.g. methotraxate, azathioprine, cyclosporine) at baseline, with the exception of inflammatory arthritis (21%), we did not adjust for this variable in the estimation models. We cannot exclude the possibility that different associations may be observed for outcome sub-types as for example between haemorrhagic and ischemic stroke or between different CHD presentations. Sensitivity analyses using MI as an outcome indicated similar results to the CHD outcome increasing confidence in the study findings. Our definition of CHD includes angina as this is a common symptom of coronary heart disease. We have re-run the analyses excluding angina from CHD codes and similar patterns were observed with respect to the significance level and direction of explore the impact of over the counter therapy and non-steroidal anti-inflammato to ory ry d dru ru ugs gs gs a NSAIDs) on study outcomes, and these could be explored as a potential mechanism in pu urp rp rpos os osef ef eful ul ully ly ly d des sig ig ign ned studies. This is an import t tan an a t t issue that dese se erv r ed ed d m m mo ore explicit attention h h han n n possible wi wi ith th t in in t the he h n nar ar arro ro row w w sc sc cop op ope e of f the e e p p prese e en nt t st tu tud dy dy. H Ho How w wev ve ver, r a a ana aly ly yse se ses s ad ad dju ju just st s ed ed ed f f fo or or gl gluc uc ucoc oc ocor or o ti tico co coid i id 46 46 6 a a and nd s sta a ati tin ns u u use e e. Be Be Beca caus us use e e fe fe fewe we wer r r th th ha an an 1 1 1% % % o o of f f ma ma matc tc che he ed d d c co on nt ntro rols ls l a a and nd d o o on nly y y a a ve very r ry mall % (<4% % %) ) ) of of f i i inf nf n la la amm mm mmat at atio io i n n n pa pa p ti ti tien en nts ts ts w w wer er ere e e o o on n n ot ot o he he h r im im immu mu muno no nosu su s pp pp ppre re ress ss ssiv iv ive e e th th her er erap ap apie ie ies s s (e.g.
http://circ.ahajournals.org/ Downloaded from the association. Also, given the objective nature of CHD, stroke, and T2DM diagnoses the definition of outcomes is unlikely to vary between cases and controls. Selection bias and confounding are also common in observational studies. As control and case groups were selected from the same sample and information was collected in the same manner, selection and information bias are likely to be minimal here. 32 Also, the observed associations were robust to sensitivity analyses supporting the validity of the findings. In the analysis of clinical data from electronic records, missing values generally present a difficulty. Marston et al. 47 observed that multiple imputation is not suitable for use in clinical data when observations may be missing not at random. We employed the missing indicator variable method but we acknowledge all methods have limitations in this context. 48 The need to impute may have slightly altered the reported absolute and relative risks. Complete case sensitivity analysis endorsed present study findings suggesting that the estimates may be rather conservative. Analyses exploring the potential mediating role of CVD risk factors are possible, however, this may be complicated by the medical surveillance of these patients that may lead to treatment of these risk factors. Our estimation models did not stratify for matching and this might result in slightly conservative estimates. 49 However, additional analyses that accounted for matching by stratification on matched-pair gave slightly higher estimates but the direction of association and significance level were similar in matching adjusted and unadjusted analyses. In the presence of unmeasured confounders, as might be the case in the present data, control of bias may be a greater concern. 
Implications for research and practice
The risk of CVD and T2DM is increased across a wide range of organ-specific and multi-system chronic inflammatory diseases, with the elevation in risk being associated with CRP as biomarker of inflammation severity. These observations suggest that similar mechanisms may be responsible for the increased risk of CVD and T2DM events across diverse inflammatory conditions. The nature of these mechanisms merits investigation in prospective studies. Over hi igh gh gher er r p p pri ri rior or orit it ity y in n n t t the he h management of participants ts ts w w with chronic t in nfl fl f am mma ma mat tory disorders. Current m man na nagement g gui ui uide e eli in ne es ar ar re e e ge ge gene nera ra all ll ly y co condit t tio o on-sp p pe e ecif f fic ic ic. . It It m m may ay b be e e d des es sir rab able le e t t to o ha ha ave ve e a a low ow ower er r h hre re esh sh hol ol o d d fo fo for r r st star ar rti ing ng n p p pre re eve vent nt tiv ive e e me me medi dic ca cal l l in in int t terv rv rven en ent tio o ons s s in in n m m mos s st t t ch ch hro ro roni ni n c c c in n nfl flam am amma ma m to to tor ry ry c c con n ndi diti ti ion n ns. s However, the he e e eff ff f ec ec ecti ti tive ve ene n n ss s s o o of f f co co conv nv n en en e ti ti ion on onal al al r ris is isk k k f f fac ac cto to tor r re re redu du duct ct ctio io on n n ap ap ppr pr proa oa oach ch ches es es t to o o CV CV CVD D D an a d T2DM M k k HR=Hazard ratios; CI=Confidence intervals.
